

OUR PIPELINE

LAST UPDATED: JANUARY 9, 2025

We are building a pipeline of *in vivo* and *ex vivo* therapies, as well as continuing to develop innovative modular platform capabilities.

IN VIVO PROGRAMS

IN VIVO CRISPR **is** the therapy
GENETIC DISEASES

PROGRAM	APPROACH	RESEARCH AND PRECLINICAL	EARLY-STAGE CLINICAL	LATE-STAGE CLINICAL	PARTNERS
NTLA-2002 Hereditary Angioedema	Knockout				Intellia LEAD
Nexiguran Ziclumeran** Transthyretin (ATTR) Amyloidosis	Knockout				Intellia LEAD REGENERON
Hemophilia B***	Insertion				Intellia LEAD REGENERON
Research Programs for Other Targets	Various				Intellia* ReCode REGENERON SPARINGVISION

EX VIVO PROGRAMS

EX VIVO CRISPR **creates** the therapy
IMMUNO-ONCOLOGY / AUTOIMMUNE DISEASE

PROGRAM	APPROACH	RESEARCH AND PRECLINICAL	EARLY-STAGE CLINICAL	LATE-STAGE CLINICAL	PARTNERS
Research Programs	Allogeneic and other				Intellia* kyverna AVENCELL ONK THERAPEUTICS

Lead refers to lead development and commercial party.

* Intellia is advancing both wholly-owned and partnered programs.
 ** Nex-z (nexiguran ziclumeran), formerly known as NTLA-2001.
 *** Hemophilia B is being advanced by Regeneron. Intellia is eligible for milestones and royalties.